Immunopathogenesis and immunotherapy of severe bullous drug eruptions

( views:, downloads: )
Author:
YANG Yong-sheng()
XU Jin-hua()
Journal Title:
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
Issue:
Volume 34, Issue 02, 2008
DOI:
Key Word:

Abstract:

  • [1]Viard I,Wehrli P,Bullani R,et al.Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.Science,1998,282(5388):490-493.
  • [2]Abe R,Shimizu T,Shibaki A,et al.Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.Am J Pathol,2003,162(5):1515-1520.
  • [3]Viard-Leveugle I,Bullani RR,Meda P,et al.Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions.J Biol Chem,2003,278(18):16183-16188.
  • [4]Nassif A,Moslehi H,Le Gouvello S,et al.Evaluation of the potential role of cytokines in toxic epidermal necrolysis.J Invest Dermatol,2004,123(5):850-855.
  • [5]Nassif A,Bensussan A,Boumsell L,et al.Toxic epidermal necrolysis:effector cells are drug-specific cytotoxic T cells.J Allergy Clin Immunol,2004,114(5):1209-1215.
  • [6]Posadas SJ,Padial A,Torres MJ,et al.Delayed reactions to drugs show levels of perforin,granzyme B,and Fas-L to be related to disease severity.J Allergy Clin Immunol,2002,109(1):155-161.
  • [7]Nassif A,Bensussan A,Dorothé e G,et al.Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.J Invest Dermatol,2002,118(4):728-733.
  • [8]Chave TA,Mortimer NJ,Sladden MJ,et al.Toxic epidermal necrolysis:current evidence,practical management and future directions.Br J Dermatol,2005,153(2):241-253.
  • [9]Paquet P,Piérard GE.Soluble fractions of tumor necrosis factor-alpha,interleukin-6 and of their receptors in toxic epidermal necrolysis:a comparison with second-degree burns.Int J Mol Med,1998,1(2):459-462.
  • [10]Lerner LH,Qureshi AA,Reddy BV,et al.Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome.J Invest Dermatol,2000,114(1):196-199.
  • [11]Paquet P,Pierard GE.Toxic epidermal necrolysis:revisiting the tentative link between early apoptosis and late necrosis(review).Int J Mol Med,2007,19(1):3-10.
  • [12]Mittmann N,Chan B,Knowles S,et al.Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.Am J Clin Dermatol,2006,7(6):359-368.
  • [13]Faye O,Roujean JC.Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins(IVIg):clinical experience to date.Drugs,2005,65(15):2085-2090.
  • [14]Arévalo JM,Lorente JA,González-Herrada C,et al.Treatment of toxic epidermal necrolysis with cyclosporin A.J Trauma,2000,48(3):473-478.
  • [15]Paquet P,Jacob E,Damas P,et al.Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis.Arch Dermatol Res,2005,297(6):266-273.
  • [16]Wolkenstein P,Latarjet J,Roujeau JC,et al.Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.Lancet,1998,352(9140):1586-1589.
  • [17]Chia FL,Leong KP.Severe cutaneous adverse reactions to drugs.Curr Opin Allergy Clin Immunol,2007,7(4):304-309.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn